nodes	percent_of_prediction	percent_of_DWPC	metapath
Levobunolol—Nausea—Vinblastine—hematologic cancer	0.000461	0.000511	CcSEcCtD
Levobunolol—Arrhythmia—Dexamethasone—hematologic cancer	0.000458	0.000508	CcSEcCtD
Levobunolol—Arrhythmia—Betamethasone—hematologic cancer	0.000458	0.000508	CcSEcCtD
Levobunolol—Pruritus—Vinorelbine—hematologic cancer	0.000457	0.000506	CcSEcCtD
Levobunolol—Pain—Mitoxantrone—hematologic cancer	0.000455	0.000505	CcSEcCtD
Levobunolol—Pain—Irinotecan—hematologic cancer	0.000455	0.000505	CcSEcCtD
Levobunolol—Bradycardia—Prednisone—hematologic cancer	0.000455	0.000504	CcSEcCtD
Levobunolol—Hypersensitivity—Thiotepa—hematologic cancer	0.000454	0.000503	CcSEcCtD
Levobunolol—Alopecia—Dexamethasone—hematologic cancer	0.000453	0.000502	CcSEcCtD
Levobunolol—Alopecia—Betamethasone—hematologic cancer	0.000453	0.000502	CcSEcCtD
Levobunolol—Diarrhoea—Bortezomib—hematologic cancer	0.000452	0.000501	CcSEcCtD
Levobunolol—Hypotension—Cisplatin—hematologic cancer	0.000452	0.000501	CcSEcCtD
Levobunolol—Urticaria—Alitretinoin—hematologic cancer	0.000451	0.000499	CcSEcCtD
Levobunolol—Headache—Lenalidomide—hematologic cancer	0.00045	0.000499	CcSEcCtD
Levobunolol—Confusional state—Etoposide—hematologic cancer	0.000446	0.000495	CcSEcCtD
Levobunolol—Urticaria—Ifosfamide—hematologic cancer	0.000445	0.000494	CcSEcCtD
Levobunolol—Cardiac arrest—Doxorubicin—hematologic cancer	0.000444	0.000492	CcSEcCtD
Levobunolol—Headache—Hydroxyurea—hematologic cancer	0.000444	0.000492	CcSEcCtD
Levobunolol—Pain—Gemcitabine—hematologic cancer	0.000443	0.000491	CcSEcCtD
Levobunolol—Asthenia—Thiotepa—hematologic cancer	0.000442	0.00049	CcSEcCtD
Levobunolol—Diarrhoea—Vinorelbine—hematologic cancer	0.000442	0.000489	CcSEcCtD
Levobunolol—Syncope—Triamcinolone—hematologic cancer	0.000441	0.000489	CcSEcCtD
Levobunolol—Ataxia—Doxorubicin—hematologic cancer	0.000439	0.000487	CcSEcCtD
Levobunolol—Hypersensitivity—Thalidomide—hematologic cancer	0.000439	0.000487	CcSEcCtD
Levobunolol—Nausea—Melphalan—hematologic cancer	0.000439	0.000486	CcSEcCtD
Levobunolol—Feeling abnormal—Mitoxantrone—hematologic cancer	0.000439	0.000486	CcSEcCtD
Levobunolol—Feeling abnormal—Irinotecan—hematologic cancer	0.000439	0.000486	CcSEcCtD
Levobunolol—Dizziness—Bortezomib—hematologic cancer	0.000437	0.000484	CcSEcCtD
Levobunolol—Pruritus—Thiotepa—hematologic cancer	0.000436	0.000483	CcSEcCtD
Levobunolol—Paraesthesia—Cisplatin—hematologic cancer	0.000434	0.000481	CcSEcCtD
Levobunolol—Loss of consciousness—Triamcinolone—hematologic cancer	0.000433	0.000479	CcSEcCtD
Levobunolol—Dyspnoea—Cisplatin—hematologic cancer	0.000431	0.000478	CcSEcCtD
Levobunolol—Shock—Prednisolone—hematologic cancer	0.00043	0.000476	CcSEcCtD
Levobunolol—Erectile dysfunction—Methotrexate—hematologic cancer	0.00043	0.000476	CcSEcCtD
Levobunolol—Asthenia—Thalidomide—hematologic cancer	0.000428	0.000474	CcSEcCtD
Levobunolol—Feeling abnormal—Gemcitabine—hematologic cancer	0.000427	0.000474	CcSEcCtD
Levobunolol—Dizziness—Vinorelbine—hematologic cancer	0.000427	0.000473	CcSEcCtD
Levobunolol—Nausea—Lenalidomide—hematologic cancer	0.000427	0.000473	CcSEcCtD
Levobunolol—Urticaria—Mitoxantrone—hematologic cancer	0.000423	0.000469	CcSEcCtD
Levobunolol—Hypersensitivity—Carmustine—hematologic cancer	0.000422	0.000468	CcSEcCtD
Levobunolol—Pruritus—Thalidomide—hematologic cancer	0.000422	0.000468	CcSEcCtD
Levobunolol—Diarrhoea—Thiotepa—hematologic cancer	0.000422	0.000467	CcSEcCtD
Levobunolol—Nausea—Hydroxyurea—hematologic cancer	0.000421	0.000466	CcSEcCtD
Levobunolol—Hypersensitivity—Alitretinoin—hematologic cancer	0.000418	0.000463	CcSEcCtD
Levobunolol—Depression—Methotrexate—hematologic cancer	0.000415	0.00046	CcSEcCtD
Levobunolol—Headache—Bortezomib—hematologic cancer	0.000414	0.000459	CcSEcCtD
Levobunolol—Hypotension—Etoposide—hematologic cancer	0.000414	0.000459	CcSEcCtD
Levobunolol—Pain—Cisplatin—hematologic cancer	0.000413	0.000458	CcSEcCtD
Levobunolol—Hypersensitivity—Ifosfamide—hematologic cancer	0.000413	0.000458	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Methotrexate—hematologic cancer	0.000412	0.000457	CcSEcCtD
Levobunolol—Asthenia—Carmustine—hematologic cancer	0.000411	0.000455	CcSEcCtD
Levobunolol—Diarrhoea—Thalidomide—hematologic cancer	0.000408	0.000452	CcSEcCtD
Levobunolol—Dizziness—Thiotepa—hematologic cancer	0.000408	0.000452	CcSEcCtD
Levobunolol—Asthenia—Alitretinoin—hematologic cancer	0.000407	0.000451	CcSEcCtD
Levobunolol—Headache—Vinorelbine—hematologic cancer	0.000404	0.000448	CcSEcCtD
Levobunolol—Conjunctivitis—Methotrexate—hematologic cancer	0.000404	0.000448	CcSEcCtD
Levobunolol—Hypersensitivity—Vincristine—hematologic cancer	0.000403	0.000446	CcSEcCtD
Levobunolol—Asthenia—Ifosfamide—hematologic cancer	0.000402	0.000446	CcSEcCtD
Levobunolol—Pruritus—Alitretinoin—hematologic cancer	0.000401	0.000445	CcSEcCtD
Levobunolol—Syncope—Dexamethasone—hematologic cancer	0.0004	0.000444	CcSEcCtD
Levobunolol—Syncope—Betamethasone—hematologic cancer	0.0004	0.000444	CcSEcCtD
Levobunolol—Arrhythmia—Prednisone—hematologic cancer	0.000399	0.000442	CcSEcCtD
Levobunolol—Feeling abnormal—Cisplatin—hematologic cancer	0.000398	0.000441	CcSEcCtD
Levobunolol—Paraesthesia—Etoposide—hematologic cancer	0.000398	0.000441	CcSEcCtD
Levobunolol—Pruritus—Ifosfamide—hematologic cancer	0.000397	0.00044	CcSEcCtD
Levobunolol—Shock—Triamcinolone—hematologic cancer	0.000395	0.000438	CcSEcCtD
Levobunolol—Dyspnoea—Etoposide—hematologic cancer	0.000395	0.000438	CcSEcCtD
Levobunolol—Alopecia—Prednisone—hematologic cancer	0.000395	0.000437	CcSEcCtD
Levobunolol—Dizziness—Thalidomide—hematologic cancer	0.000394	0.000437	CcSEcCtD
Levobunolol—Nausea—Bortezomib—hematologic cancer	0.000393	0.000435	CcSEcCtD
Levobunolol—Loss of consciousness—Dexamethasone—hematologic cancer	0.000392	0.000435	CcSEcCtD
Levobunolol—Loss of consciousness—Betamethasone—hematologic cancer	0.000392	0.000435	CcSEcCtD
Levobunolol—Hypersensitivity—Irinotecan—hematologic cancer	0.000392	0.000435	CcSEcCtD
Levobunolol—Hypersensitivity—Mitoxantrone—hematologic cancer	0.000392	0.000435	CcSEcCtD
Levobunolol—Asthenia—Vincristine—hematologic cancer	0.000392	0.000435	CcSEcCtD
Levobunolol—Paraesthesia—Prednisolone—hematologic cancer	0.000392	0.000435	CcSEcCtD
Levobunolol—Diarrhoea—Carmustine—hematologic cancer	0.000392	0.000434	CcSEcCtD
Levobunolol—Nausea—Bleomycin—hematologic cancer	0.00039	0.000432	CcSEcCtD
Levobunolol—Diarrhoea—Alitretinoin—hematologic cancer	0.000388	0.00043	CcSEcCtD
Levobunolol—Headache—Thiotepa—hematologic cancer	0.000386	0.000428	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Epirubicin—hematologic cancer	0.000386	0.000428	CcSEcCtD
Levobunolol—Diarrhoea—Ifosfamide—hematologic cancer	0.000384	0.000425	CcSEcCtD
Levobunolol—Nausea—Vinorelbine—hematologic cancer	0.000383	0.000425	CcSEcCtD
Levobunolol—Asthenia—Irinotecan—hematologic cancer	0.000382	0.000423	CcSEcCtD
Levobunolol—Asthenia—Mitoxantrone—hematologic cancer	0.000382	0.000423	CcSEcCtD
Levobunolol—Dizziness—Carmustine—hematologic cancer	0.000379	0.00042	CcSEcCtD
Levobunolol—Pain—Etoposide—hematologic cancer	0.000379	0.00042	CcSEcCtD
Levobunolol—Conjunctivitis—Epirubicin—hematologic cancer	0.000378	0.000419	CcSEcCtD
Levobunolol—Dizziness—Alitretinoin—hematologic cancer	0.000375	0.000416	CcSEcCtD
Levobunolol—Diarrhoea—Vincristine—hematologic cancer	0.000374	0.000415	CcSEcCtD
Levobunolol—Headache—Thalidomide—hematologic cancer	0.000374	0.000414	CcSEcCtD
Levobunolol—Pain—Prednisolone—hematologic cancer	0.000373	0.000414	CcSEcCtD
Levobunolol—Asthenia—Gemcitabine—hematologic cancer	0.000372	0.000412	CcSEcCtD
Levobunolol—Dizziness—Ifosfamide—hematologic cancer	0.000371	0.000411	CcSEcCtD
Levobunolol—Pruritus—Gemcitabine—hematologic cancer	0.000367	0.000407	CcSEcCtD
Levobunolol—Nausea—Thiotepa—hematologic cancer	0.000366	0.000406	CcSEcCtD
Levobunolol—Feeling abnormal—Etoposide—hematologic cancer	0.000365	0.000404	CcSEcCtD
Levobunolol—Diarrhoea—Mitoxantrone—hematologic cancer	0.000364	0.000404	CcSEcCtD
Levobunolol—Diarrhoea—Irinotecan—hematologic cancer	0.000364	0.000404	CcSEcCtD
Levobunolol—Dizziness—Vincristine—hematologic cancer	0.000361	0.000401	CcSEcCtD
Levobunolol—Paraesthesia—Triamcinolone—hematologic cancer	0.000361	0.0004	CcSEcCtD
Levobunolol—Feeling abnormal—Prednisolone—hematologic cancer	0.00036	0.000399	CcSEcCtD
Levobunolol—Visual impairment—Methotrexate—hematologic cancer	0.00036	0.000399	CcSEcCtD
Levobunolol—Headache—Carmustine—hematologic cancer	0.000359	0.000398	CcSEcCtD
Levobunolol—Shock—Betamethasone—hematologic cancer	0.000359	0.000397	CcSEcCtD
Levobunolol—Shock—Dexamethasone—hematologic cancer	0.000359	0.000397	CcSEcCtD
Levobunolol—Dyspnoea—Triamcinolone—hematologic cancer	0.000358	0.000397	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Doxorubicin—hematologic cancer	0.000357	0.000396	CcSEcCtD
Levobunolol—Hypersensitivity—Cisplatin—hematologic cancer	0.000356	0.000395	CcSEcCtD
Levobunolol—Bradycardia—Epirubicin—hematologic cancer	0.000356	0.000394	CcSEcCtD
Levobunolol—Headache—Alitretinoin—hematologic cancer	0.000355	0.000394	CcSEcCtD
Levobunolol—Diarrhoea—Gemcitabine—hematologic cancer	0.000355	0.000393	CcSEcCtD
Levobunolol—Nausea—Thalidomide—hematologic cancer	0.000354	0.000393	CcSEcCtD
Levobunolol—Erythema multiforme—Methotrexate—hematologic cancer	0.000353	0.000391	CcSEcCtD
Levobunolol—Dizziness—Irinotecan—hematologic cancer	0.000352	0.00039	CcSEcCtD
Levobunolol—Urticaria—Etoposide—hematologic cancer	0.000352	0.00039	CcSEcCtD
Levobunolol—Conjunctivitis—Doxorubicin—hematologic cancer	0.00035	0.000388	CcSEcCtD
Levobunolol—Syncope—Prednisone—hematologic cancer	0.000349	0.000386	CcSEcCtD
Levobunolol—Urticaria—Prednisolone—hematologic cancer	0.000347	0.000385	CcSEcCtD
Levobunolol—Asthenia—Cisplatin—hematologic cancer	0.000347	0.000384	CcSEcCtD
Levobunolol—Pain—Triamcinolone—hematologic cancer	0.000343	0.000381	CcSEcCtD
Levobunolol—Headache—Vincristine—hematologic cancer	0.000342	0.00038	CcSEcCtD
Levobunolol—Loss of consciousness—Prednisone—hematologic cancer	0.000342	0.000379	CcSEcCtD
Levobunolol—Hypotension—Dexamethasone—hematologic cancer	0.000341	0.000377	CcSEcCtD
Levobunolol—Hypotension—Betamethasone—hematologic cancer	0.000341	0.000377	CcSEcCtD
Levobunolol—Nausea—Carmustine—hematologic cancer	0.00034	0.000377	CcSEcCtD
Levobunolol—Nausea—Alitretinoin—hematologic cancer	0.000337	0.000373	CcSEcCtD
Levobunolol—Visual impairment—Epirubicin—hematologic cancer	0.000337	0.000373	CcSEcCtD
Levobunolol—Headache—Mitoxantrone—hematologic cancer	0.000333	0.00037	CcSEcCtD
Levobunolol—Headache—Irinotecan—hematologic cancer	0.000333	0.00037	CcSEcCtD
Levobunolol—Nausea—Ifosfamide—hematologic cancer	0.000333	0.000369	CcSEcCtD
Levobunolol—Feeling abnormal—Triamcinolone—hematologic cancer	0.000331	0.000367	CcSEcCtD
Levobunolol—Diarrhoea—Cisplatin—hematologic cancer	0.000331	0.000367	CcSEcCtD
Levobunolol—Erythema multiforme—Epirubicin—hematologic cancer	0.00033	0.000366	CcSEcCtD
Levobunolol—Alopecia—Methotrexate—hematologic cancer	0.00033	0.000366	CcSEcCtD
Levobunolol—Bradycardia—Doxorubicin—hematologic cancer	0.000329	0.000365	CcSEcCtD
Levobunolol—Paraesthesia—Betamethasone—hematologic cancer	0.000327	0.000363	CcSEcCtD
Levobunolol—Paraesthesia—Dexamethasone—hematologic cancer	0.000327	0.000363	CcSEcCtD
Levobunolol—Hypersensitivity—Etoposide—hematologic cancer	0.000326	0.000362	CcSEcCtD
Levobunolol—Headache—Gemcitabine—hematologic cancer	0.000325	0.00036	CcSEcCtD
Levobunolol—Nausea—Vincristine—hematologic cancer	0.000325	0.00036	CcSEcCtD
Levobunolol—Hypersensitivity—Prednisolone—hematologic cancer	0.000322	0.000357	CcSEcCtD
Levobunolol—Urticaria—Triamcinolone—hematologic cancer	0.000319	0.000354	CcSEcCtD
Levobunolol—Asthenia—Etoposide—hematologic cancer	0.000318	0.000352	CcSEcCtD
Levobunolol—Nausea—Mitoxantrone—hematologic cancer	0.000316	0.00035	CcSEcCtD
Levobunolol—Nausea—Irinotecan—hematologic cancer	0.000316	0.00035	CcSEcCtD
Levobunolol—Pruritus—Etoposide—hematologic cancer	0.000313	0.000347	CcSEcCtD
Levobunolol—Shock—Prednisone—hematologic cancer	0.000312	0.000346	CcSEcCtD
Levobunolol—Arrhythmia—Epirubicin—hematologic cancer	0.000312	0.000346	CcSEcCtD
Levobunolol—Pain—Dexamethasone—hematologic cancer	0.000312	0.000345	CcSEcCtD
Levobunolol—Pain—Betamethasone—hematologic cancer	0.000312	0.000345	CcSEcCtD
Levobunolol—Visual impairment—Doxorubicin—hematologic cancer	0.000312	0.000345	CcSEcCtD
Levobunolol—Alopecia—Epirubicin—hematologic cancer	0.000309	0.000342	CcSEcCtD
Levobunolol—Nausea—Gemcitabine—hematologic cancer	0.000308	0.000341	CcSEcCtD
Levobunolol—Erythema multiforme—Doxorubicin—hematologic cancer	0.000306	0.000339	CcSEcCtD
Levobunolol—Diarrhoea—Etoposide—hematologic cancer	0.000303	0.000336	CcSEcCtD
Levobunolol—Feeling abnormal—Dexamethasone—hematologic cancer	0.0003	0.000333	CcSEcCtD
Levobunolol—Feeling abnormal—Betamethasone—hematologic cancer	0.0003	0.000333	CcSEcCtD
Levobunolol—Hypersensitivity—Triamcinolone—hematologic cancer	0.000296	0.000328	CcSEcCtD
Levobunolol—Dizziness—Etoposide—hematologic cancer	0.000293	0.000325	CcSEcCtD
Levobunolol—Urticaria—Betamethasone—hematologic cancer	0.00029	0.000321	CcSEcCtD
Levobunolol—Urticaria—Dexamethasone—hematologic cancer	0.00029	0.000321	CcSEcCtD
Levobunolol—Dizziness—Prednisolone—hematologic cancer	0.000289	0.00032	CcSEcCtD
Levobunolol—Arrhythmia—Doxorubicin—hematologic cancer	0.000289	0.00032	CcSEcCtD
Levobunolol—Asthenia—Triamcinolone—hematologic cancer	0.000288	0.000319	CcSEcCtD
Levobunolol—Nausea—Cisplatin—hematologic cancer	0.000287	0.000318	CcSEcCtD
Levobunolol—Alopecia—Doxorubicin—hematologic cancer	0.000286	0.000317	CcSEcCtD
Levobunolol—Paraesthesia—Prednisone—hematologic cancer	0.000285	0.000316	CcSEcCtD
Levobunolol—Pruritus—Triamcinolone—hematologic cancer	0.000284	0.000315	CcSEcCtD
Levobunolol—Headache—Etoposide—hematologic cancer	0.000277	0.000307	CcSEcCtD
Levobunolol—Chest pain—Methotrexate—hematologic cancer	0.000277	0.000307	CcSEcCtD
Levobunolol—Headache—Prednisolone—hematologic cancer	0.000274	0.000303	CcSEcCtD
Levobunolol—Syncope—Epirubicin—hematologic cancer	0.000273	0.000302	CcSEcCtD
Levobunolol—Palpitations—Epirubicin—hematologic cancer	0.000269	0.000298	CcSEcCtD
Levobunolol—Confusional state—Methotrexate—hematologic cancer	0.000267	0.000296	CcSEcCtD
Levobunolol—Loss of consciousness—Epirubicin—hematologic cancer	0.000267	0.000296	CcSEcCtD
Levobunolol—Dizziness—Triamcinolone—hematologic cancer	0.000266	0.000294	CcSEcCtD
Levobunolol—Nausea—Etoposide—hematologic cancer	0.000263	0.000292	CcSEcCtD
Levobunolol—Feeling abnormal—Prednisone—hematologic cancer	0.000262	0.00029	CcSEcCtD
Levobunolol—Asthenia—Dexamethasone—hematologic cancer	0.000261	0.00029	CcSEcCtD
Levobunolol—Asthenia—Betamethasone—hematologic cancer	0.000261	0.00029	CcSEcCtD
Levobunolol—Nausea—Prednisolone—hematologic cancer	0.000259	0.000288	CcSEcCtD
Levobunolol—Chest pain—Epirubicin—hematologic cancer	0.000259	0.000287	CcSEcCtD
Levobunolol—Pruritus—Betamethasone—hematologic cancer	0.000258	0.000286	CcSEcCtD
Levobunolol—Pruritus—Dexamethasone—hematologic cancer	0.000258	0.000286	CcSEcCtD
Levobunolol—Syncope—Doxorubicin—hematologic cancer	0.000252	0.00028	CcSEcCtD
Levobunolol—Urticaria—Prednisone—hematologic cancer	0.000252	0.000279	CcSEcCtD
Levobunolol—Headache—Triamcinolone—hematologic cancer	0.000252	0.000279	CcSEcCtD
Levobunolol—Confusional state—Epirubicin—hematologic cancer	0.00025	0.000277	CcSEcCtD
Levobunolol—Diarrhoea—Betamethasone—hematologic cancer	0.000249	0.000276	CcSEcCtD
Levobunolol—Diarrhoea—Dexamethasone—hematologic cancer	0.000249	0.000276	CcSEcCtD
Levobunolol—Palpitations—Doxorubicin—hematologic cancer	0.000249	0.000276	CcSEcCtD
Levobunolol—Hypotension—Methotrexate—hematologic cancer	0.000248	0.000275	CcSEcCtD
Levobunolol—Loss of consciousness—Doxorubicin—hematologic cancer	0.000247	0.000274	CcSEcCtD
Levobunolol—Shock—Epirubicin—hematologic cancer	0.000244	0.000271	CcSEcCtD
Levobunolol—Dizziness—Dexamethasone—hematologic cancer	0.000241	0.000267	CcSEcCtD
Levobunolol—Dizziness—Betamethasone—hematologic cancer	0.000241	0.000267	CcSEcCtD
Levobunolol—Chest pain—Doxorubicin—hematologic cancer	0.00024	0.000266	CcSEcCtD
Levobunolol—Nausea—Triamcinolone—hematologic cancer	0.000239	0.000264	CcSEcCtD
Levobunolol—Paraesthesia—Methotrexate—hematologic cancer	0.000238	0.000264	CcSEcCtD
Levobunolol—Dyspnoea—Methotrexate—hematologic cancer	0.000236	0.000262	CcSEcCtD
Levobunolol—Hypersensitivity—Prednisone—hematologic cancer	0.000234	0.000259	CcSEcCtD
Levobunolol—Hypotension—Epirubicin—hematologic cancer	0.000232	0.000257	CcSEcCtD
Levobunolol—Confusional state—Doxorubicin—hematologic cancer	0.000232	0.000257	CcSEcCtD
Levobunolol—Headache—Dexamethasone—hematologic cancer	0.000228	0.000253	CcSEcCtD
Levobunolol—Headache—Betamethasone—hematologic cancer	0.000228	0.000253	CcSEcCtD
Levobunolol—Asthenia—Prednisone—hematologic cancer	0.000228	0.000252	CcSEcCtD
Levobunolol—Pain—Methotrexate—hematologic cancer	0.000227	0.000251	CcSEcCtD
Levobunolol—Shock—Doxorubicin—hematologic cancer	0.000226	0.00025	CcSEcCtD
Levobunolol—Pruritus—Prednisone—hematologic cancer	0.000225	0.000249	CcSEcCtD
Levobunolol—Paraesthesia—Epirubicin—hematologic cancer	0.000223	0.000247	CcSEcCtD
Levobunolol—Dyspnoea—Epirubicin—hematologic cancer	0.000221	0.000245	CcSEcCtD
Levobunolol—Feeling abnormal—Methotrexate—hematologic cancer	0.000219	0.000242	CcSEcCtD
Levobunolol—Diarrhoea—Prednisone—hematologic cancer	0.000217	0.000241	CcSEcCtD
Levobunolol—Nausea—Dexamethasone—hematologic cancer	0.000216	0.00024	CcSEcCtD
Levobunolol—Nausea—Betamethasone—hematologic cancer	0.000216	0.00024	CcSEcCtD
Levobunolol—Hypotension—Doxorubicin—hematologic cancer	0.000215	0.000238	CcSEcCtD
Levobunolol—Pain—Epirubicin—hematologic cancer	0.000212	0.000235	CcSEcCtD
Levobunolol—Urticaria—Methotrexate—hematologic cancer	0.000211	0.000234	CcSEcCtD
Levobunolol—Dizziness—Prednisone—hematologic cancer	0.00021	0.000233	CcSEcCtD
Levobunolol—Paraesthesia—Doxorubicin—hematologic cancer	0.000206	0.000229	CcSEcCtD
Levobunolol—Dyspnoea—Doxorubicin—hematologic cancer	0.000205	0.000227	CcSEcCtD
Levobunolol—Feeling abnormal—Epirubicin—hematologic cancer	0.000205	0.000227	CcSEcCtD
Levobunolol—Headache—Prednisone—hematologic cancer	0.000199	0.00022	CcSEcCtD
Levobunolol—Urticaria—Epirubicin—hematologic cancer	0.000197	0.000219	CcSEcCtD
Levobunolol—Pain—Doxorubicin—hematologic cancer	0.000196	0.000218	CcSEcCtD
Levobunolol—Hypersensitivity—Methotrexate—hematologic cancer	0.000195	0.000217	CcSEcCtD
Levobunolol—Asthenia—Methotrexate—hematologic cancer	0.00019	0.000211	CcSEcCtD
Levobunolol—Feeling abnormal—Doxorubicin—hematologic cancer	0.000189	0.00021	CcSEcCtD
Levobunolol—Nausea—Prednisone—hematologic cancer	0.000189	0.000209	CcSEcCtD
Levobunolol—Pruritus—Methotrexate—hematologic cancer	0.000188	0.000208	CcSEcCtD
Levobunolol—Hypersensitivity—Epirubicin—hematologic cancer	0.000183	0.000203	CcSEcCtD
Levobunolol—Urticaria—Doxorubicin—hematologic cancer	0.000182	0.000202	CcSEcCtD
Levobunolol—Diarrhoea—Methotrexate—hematologic cancer	0.000181	0.000201	CcSEcCtD
Levobunolol—Asthenia—Epirubicin—hematologic cancer	0.000178	0.000197	CcSEcCtD
Levobunolol—Pruritus—Epirubicin—hematologic cancer	0.000176	0.000195	CcSEcCtD
Levobunolol—Dizziness—Methotrexate—hematologic cancer	0.000175	0.000194	CcSEcCtD
Levobunolol—Diarrhoea—Epirubicin—hematologic cancer	0.00017	0.000188	CcSEcCtD
Levobunolol—Hypersensitivity—Doxorubicin—hematologic cancer	0.000169	0.000188	CcSEcCtD
Levobunolol—Headache—Methotrexate—hematologic cancer	0.000166	0.000184	CcSEcCtD
Levobunolol—Asthenia—Doxorubicin—hematologic cancer	0.000165	0.000183	CcSEcCtD
Levobunolol—Dizziness—Epirubicin—hematologic cancer	0.000164	0.000182	CcSEcCtD
Levobunolol—Pruritus—Doxorubicin—hematologic cancer	0.000162	0.00018	CcSEcCtD
Levobunolol—Nausea—Methotrexate—hematologic cancer	0.000158	0.000175	CcSEcCtD
Levobunolol—Diarrhoea—Doxorubicin—hematologic cancer	0.000157	0.000174	CcSEcCtD
Levobunolol—Headache—Epirubicin—hematologic cancer	0.000155	0.000172	CcSEcCtD
Levobunolol—Dizziness—Doxorubicin—hematologic cancer	0.000152	0.000168	CcSEcCtD
Levobunolol—Nausea—Epirubicin—hematologic cancer	0.000147	0.000163	CcSEcCtD
Levobunolol—Headache—Doxorubicin—hematologic cancer	0.000144	0.000159	CcSEcCtD
Levobunolol—Nausea—Doxorubicin—hematologic cancer	0.000136	0.000151	CcSEcCtD
Levobunolol—Timolol—ABCB1—hematologic cancer	0.000105	0.484	CrCbGaD
Levobunolol—Nadolol—ABCB1—hematologic cancer	8.38e-05	0.384	CrCbGaD
Levobunolol—ADRB1—Signaling Pathways—STAT5B—hematologic cancer	6.04e-05	0.00062	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—JAK1—hematologic cancer	6.02e-05	0.000617	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PRKCG—hematologic cancer	6.02e-05	0.000617	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—RAC2—hematologic cancer	6.01e-05	0.000616	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—DKK1—hematologic cancer	5.96e-05	0.000611	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—STAT5B—hematologic cancer	5.91e-05	0.000606	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ADCY7—hematologic cancer	5.87e-05	0.000602	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CSF2—hematologic cancer	5.79e-05	0.000594	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—IL2RA—hematologic cancer	5.75e-05	0.000589	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—ADCY7—hematologic cancer	5.74e-05	0.000589	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—XIAP—hematologic cancer	5.71e-05	0.000585	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CSF2—hematologic cancer	5.66e-05	0.000581	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—IL2RA—hematologic cancer	5.62e-05	0.000577	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—JAK1—hematologic cancer	5.59e-05	0.000573	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PRKCG—hematologic cancer	5.59e-05	0.000573	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—XIAP—hematologic cancer	5.58e-05	0.000573	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SH2B3—hematologic cancer	5.56e-05	0.000571	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SMARCA4—hematologic cancer	5.56e-05	0.000571	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GZMB—hematologic cancer	5.53e-05	0.000567	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PRKCG—hematologic cancer	5.46e-05	0.000561	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—JAK1—hematologic cancer	5.46e-05	0.000561	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SMARCA4—hematologic cancer	5.44e-05	0.000558	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SH2B3—hematologic cancer	5.44e-05	0.000558	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GZMB—hematologic cancer	5.41e-05	0.000555	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CTNNA1—hematologic cancer	5.4e-05	0.000554	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—EIF4EBP1—hematologic cancer	5.37e-05	0.00055	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HSPB1—hematologic cancer	5.37e-05	0.00055	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CCL3—hematologic cancer	5.37e-05	0.00055	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PTHLH—hematologic cancer	5.31e-05	0.000544	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SDC1—hematologic cancer	5.31e-05	0.000544	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CTNNA1—hematologic cancer	5.28e-05	0.000542	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—EIF4EBP1—hematologic cancer	5.25e-05	0.000538	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HSPB1—hematologic cancer	5.25e-05	0.000538	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CCL3—hematologic cancer	5.25e-05	0.000538	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—IL2RA—hematologic cancer	5.22e-05	0.000535	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PTHLH—hematologic cancer	5.19e-05	0.000532	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SDC1—hematologic cancer	5.19e-05	0.000532	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PTGER4—hematologic cancer	5.17e-05	0.00053	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—LCK—hematologic cancer	5.14e-05	0.000527	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—IL2RA—hematologic cancer	5.1e-05	0.000524	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PTGER4—hematologic cancer	5.05e-05	0.000518	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—H3F3A—hematologic cancer	5.04e-05	0.000517	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—LCK—hematologic cancer	5.03e-05	0.000516	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—H3F3A—hematologic cancer	4.93e-05	0.000505	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PRKCZ—hematologic cancer	4.9e-05	0.000502	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PRKCZ—hematologic cancer	4.79e-05	0.000491	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CG—hematologic cancer	4.79e-05	0.000491	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PARP1—hematologic cancer	4.73e-05	0.000485	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CG—hematologic cancer	4.68e-05	0.00048	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—FBXW7—hematologic cancer	4.65e-05	0.000477	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PARP1—hematologic cancer	4.63e-05	0.000475	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CXCR4—hematologic cancer	4.56e-05	0.000468	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HDAC2—hematologic cancer	4.56e-05	0.000468	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—FBXW7—hematologic cancer	4.55e-05	0.000467	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HDAC2—hematologic cancer	4.46e-05	0.000458	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CXCR4—hematologic cancer	4.46e-05	0.000458	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CBL—hematologic cancer	4.45e-05	0.000456	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IL3—hematologic cancer	4.4e-05	0.000451	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CBL—hematologic cancer	4.35e-05	0.000446	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CG—hematologic cancer	4.35e-05	0.000446	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PTPN1—hematologic cancer	4.33e-05	0.000444	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IL3—hematologic cancer	4.3e-05	0.000441	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PTPN11—hematologic cancer	4.27e-05	0.000438	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—RASGRP1—hematologic cancer	4.26e-05	0.000437	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CG—hematologic cancer	4.25e-05	0.000436	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HSP90AA1—hematologic cancer	4.24e-05	0.000435	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SYK—hematologic cancer	4.24e-05	0.000435	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PTPN1—hematologic cancer	4.23e-05	0.000434	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CD—hematologic cancer	4.21e-05	0.000432	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PTPN11—hematologic cancer	4.18e-05	0.000428	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—RASGRP1—hematologic cancer	4.16e-05	0.000427	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HSP90AA1—hematologic cancer	4.15e-05	0.000426	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SYK—hematologic cancer	4.15e-05	0.000426	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CREB1—hematologic cancer	4.14e-05	0.000424	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CD—hematologic cancer	4.12e-05	0.000422	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—STAT1—hematologic cancer	4.09e-05	0.00042	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CCL2—hematologic cancer	4.05e-05	0.000415	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CREB1—hematologic cancer	4.05e-05	0.000415	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—IL6R—hematologic cancer	4.04e-05	0.000414	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—STAT1—hematologic cancer	4e-05	0.00041	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3R1—hematologic cancer	3.97e-05	0.000408	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CCL2—hematologic cancer	3.96e-05	0.000406	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—IL6R—hematologic cancer	3.95e-05	0.000405	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3R1—hematologic cancer	3.89e-05	0.000399	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—JAK2—hematologic cancer	3.86e-05	0.000396	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—MAP2K1—hematologic cancer	3.85e-05	0.000395	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GRB2—hematologic cancer	3.83e-05	0.000393	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CD—hematologic cancer	3.82e-05	0.000392	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PDGFA—hematologic cancer	3.82e-05	0.000392	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—JAK2—hematologic cancer	3.78e-05	0.000387	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—KITLG—hematologic cancer	3.76e-05	0.000386	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—MAP2K1—hematologic cancer	3.76e-05	0.000386	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GRB2—hematologic cancer	3.74e-05	0.000384	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CD—hematologic cancer	3.74e-05	0.000383	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PDGFA—hematologic cancer	3.73e-05	0.000383	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—KITLG—hematologic cancer	3.68e-05	0.000378	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—STAT5A—hematologic cancer	3.68e-05	0.000377	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CB—hematologic cancer	3.67e-05	0.000376	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CDKN2B—hematologic cancer	3.65e-05	0.000374	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3R1—hematologic cancer	3.61e-05	0.00037	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—STAT5A—hematologic cancer	3.6e-05	0.000369	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CB—hematologic cancer	3.59e-05	0.000368	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CDKN2B—hematologic cancer	3.57e-05	0.000366	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3R1—hematologic cancer	3.53e-05	0.000362	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CD86—hematologic cancer	3.53e-05	0.000362	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—JAK2—hematologic cancer	3.51e-05	0.00036	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HES1—hematologic cancer	3.48e-05	0.000357	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NCOR1—hematologic cancer	3.46e-05	0.000355	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CD86—hematologic cancer	3.45e-05	0.000354	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—JAK2—hematologic cancer	3.43e-05	0.000352	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—FGF1—hematologic cancer	3.42e-05	0.000351	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CSF2—hematologic cancer	3.42e-05	0.000351	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HES1—hematologic cancer	3.4e-05	0.000349	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NCOR1—hematologic cancer	3.38e-05	0.000347	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—FOXO1—hematologic cancer	3.37e-05	0.000346	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—IL2—hematologic cancer	3.37e-05	0.000346	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PDGFRB—hematologic cancer	3.36e-05	0.000345	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—FGF1—hematologic cancer	3.34e-05	0.000343	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CSF2—hematologic cancer	3.34e-05	0.000343	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CB—hematologic cancer	3.33e-05	0.000342	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PDGFRA—hematologic cancer	3.31e-05	0.00034	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PRKCG—hematologic cancer	3.3e-05	0.000339	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—JAK1—hematologic cancer	3.3e-05	0.000339	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—FOXO1—hematologic cancer	3.3e-05	0.000338	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—IL2—hematologic cancer	3.29e-05	0.000338	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PDGFRB—hematologic cancer	3.29e-05	0.000338	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CB—hematologic cancer	3.26e-05	0.000334	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PDGFRA—hematologic cancer	3.24e-05	0.000332	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—JAK1—hematologic cancer	3.23e-05	0.000331	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PRKCG—hematologic cancer	3.23e-05	0.000331	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IL2RA—hematologic cancer	3.08e-05	0.000316	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—IL2—hematologic cancer	3.06e-05	0.000314	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TERT—hematologic cancer	3.05e-05	0.000313	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IL2RA—hematologic cancer	3.01e-05	0.000309	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—IL2—hematologic cancer	2.99e-05	0.000307	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—TERT—hematologic cancer	2.98e-05	0.000306	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PDGFB—hematologic cancer	2.97e-05	0.000305	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PDGFB—hematologic cancer	2.91e-05	0.000298	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TSC2—hematologic cancer	2.91e-05	0.000298	CbGpPWpGaD
Levobunolol—Propranolol—ABCB1—hematologic cancer	2.87e-05	0.132	CrCbGaD
Levobunolol—ADRB2—Signaling Pathways—TSC2—hematologic cancer	2.84e-05	0.000292	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—FGFR3—hematologic cancer	2.8e-05	0.000287	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MAPK14—hematologic cancer	2.77e-05	0.000284	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—FGFR3—hematologic cancer	2.74e-05	0.000281	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ESR1—hematologic cancer	2.72e-05	0.000279	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MAPK14—hematologic cancer	2.71e-05	0.000278	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—FN1—hematologic cancer	2.68e-05	0.000275	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—ESR1—hematologic cancer	2.66e-05	0.000273	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—BAD—hematologic cancer	2.65e-05	0.000272	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NFKBIA—hematologic cancer	2.65e-05	0.000272	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NOTCH1—hematologic cancer	2.63e-05	0.000269	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—FN1—hematologic cancer	2.62e-05	0.000269	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—BAD—hematologic cancer	2.59e-05	0.000266	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NFKBIA—hematologic cancer	2.59e-05	0.000266	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CD80—hematologic cancer	2.57e-05	0.000264	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NOTCH1—hematologic cancer	2.57e-05	0.000263	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—KIT—hematologic cancer	2.57e-05	0.000263	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CG—hematologic cancer	2.57e-05	0.000263	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—NRAS—hematologic cancer	2.57e-05	0.000263	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PTPN11—hematologic cancer	2.52e-05	0.000259	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CD80—hematologic cancer	2.52e-05	0.000258	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—KIT—hematologic cancer	2.51e-05	0.000258	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CG—hematologic cancer	2.51e-05	0.000258	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—NRAS—hematologic cancer	2.51e-05	0.000258	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PTPN11—hematologic cancer	2.47e-05	0.000253	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—MAPK3—hematologic cancer	2.46e-05	0.000252	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CREB1—hematologic cancer	2.44e-05	0.000251	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—BRAF—hematologic cancer	2.41e-05	0.000248	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—MAPK3—hematologic cancer	2.41e-05	0.000247	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CCL2—hematologic cancer	2.39e-05	0.000245	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CREB1—hematologic cancer	2.39e-05	0.000245	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IL6R—hematologic cancer	2.38e-05	0.000245	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CREBBP—hematologic cancer	2.38e-05	0.000244	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—BRAF—hematologic cancer	2.36e-05	0.000242	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CCL2—hematologic cancer	2.34e-05	0.00024	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IL6R—hematologic cancer	2.33e-05	0.000239	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CREBBP—hematologic cancer	2.33e-05	0.000239	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MAP2K1—hematologic cancer	2.27e-05	0.000233	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CD—hematologic cancer	2.26e-05	0.000232	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CA—hematologic cancer	2.24e-05	0.000229	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	2.22e-05	0.000228	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—KRAS—hematologic cancer	2.21e-05	0.000227	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	2.21e-05	0.000226	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	2.19e-05	0.000224	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	2.16e-05	0.000222	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—FGF2—hematologic cancer	2.16e-05	0.000222	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3R1—hematologic cancer	2.13e-05	0.000219	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—FGF2—hematologic cancer	2.11e-05	0.000217	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	2.09e-05	0.000214	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—JAK2—hematologic cancer	2.07e-05	0.000212	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CA—hematologic cancer	2.03e-05	0.000208	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—JAK2—hematologic cancer	2.03e-05	0.000208	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MDM2—hematologic cancer	2.02e-05	0.000207	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	1.99e-05	0.000204	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MDM2—hematologic cancer	1.98e-05	0.000203	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CB—hematologic cancer	1.97e-05	0.000202	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MTOR—hematologic cancer	1.97e-05	0.000202	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MTOR—hematologic cancer	1.92e-05	0.000197	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	1.92e-05	0.000197	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—HRAS—hematologic cancer	1.88e-05	0.000193	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CDKN1B—hematologic cancer	1.85e-05	0.000189	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	1.84e-05	0.000188	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—AKT1—hematologic cancer	1.83e-05	0.000187	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CASP3—hematologic cancer	1.81e-05	0.000186	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IL2—hematologic cancer	1.81e-05	0.000185	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	1.81e-05	0.000185	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—IL6—hematologic cancer	1.8e-05	0.000184	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	1.79e-05	0.000183	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CASP3—hematologic cancer	1.77e-05	0.000182	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IL2—hematologic cancer	1.77e-05	0.000181	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CCND1—hematologic cancer	1.76e-05	0.000181	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—IL6—hematologic cancer	1.76e-05	0.00018	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—JUN—hematologic cancer	1.76e-05	0.00018	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CCND1—hematologic cancer	1.72e-05	0.000177	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—JUN—hematologic cancer	1.72e-05	0.000176	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	1.7e-05	0.000175	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PTEN—hematologic cancer	1.7e-05	0.000174	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	1.67e-05	0.000171	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	1.66e-05	0.000171	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PTEN—hematologic cancer	1.66e-05	0.000171	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	1.66e-05	0.00017	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	1.63e-05	0.000167	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	1.62e-05	0.000166	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—EP300—hematologic cancer	1.62e-05	0.000166	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—EP300—hematologic cancer	1.59e-05	0.000163	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SRC—hematologic cancer	1.58e-05	0.000162	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SRC—hematologic cancer	1.54e-05	0.000158	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	1.54e-05	0.000158	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—STAT3—hematologic cancer	1.52e-05	0.000156	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NRAS—hematologic cancer	1.52e-05	0.000156	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	1.5e-05	0.000154	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—STAT3—hematologic cancer	1.49e-05	0.000153	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NRAS—hematologic cancer	1.48e-05	0.000152	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	1.45e-05	0.000149	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	1.42e-05	0.000146	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MYC—hematologic cancer	1.41e-05	0.000145	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	1.41e-05	0.000145	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MYC—hematologic cancer	1.38e-05	0.000142	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	1.38e-05	0.000141	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—KRAS—hematologic cancer	1.31e-05	0.000134	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—KRAS—hematologic cancer	1.28e-05	0.000131	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	1.2e-05	0.000123	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	1.17e-05	0.00012	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TP53—hematologic cancer	1.16e-05	0.000119	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—TP53—hematologic cancer	1.13e-05	0.000116	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HRAS—hematologic cancer	1.11e-05	0.000114	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HRAS—hematologic cancer	1.09e-05	0.000111	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IL6—hematologic cancer	1.06e-05	0.000109	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IL6—hematologic cancer	1.04e-05	0.000107	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—AKT1—hematologic cancer	9.8e-06	0.000101	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—AKT1—hematologic cancer	9.58e-06	9.83e-05	CbGpPWpGaD
